I am also buying

Top Glove has bottomed

Healthcare perform well in recessionary environment

Bursa Small and Mid Cap Equity Strategy (buy-side call)
1. Healthcare stocks (Top Glove, Kotra Industries, Apex Healthcare, Malaysian Genomics Resources)


Bursa Small and Mid Cap (sell-side analyst calls)
1. Commodities (Hengyuan, Hibiscus Petroleum, Coastal Contract)
2. Palm Oil (TSH Resources, Sarawak Oil Palm)
3. Financials (Alliance Bank, AmBank)

rr88 is a legend, he shorted Hengyuan. I trust his call

Good close. I am holding until next week

Happy weekend

It is now evident that CAR-T therapy has revolutionized cancer research and treatment. Within a
few years, substantial progress has been made, particularly for patients with certain hematological
malignancies who had progressed after several lines of therapies and had almost exhausted all
potential treatments. Furthermore, there are new indications for continued success of CAR-T therapies.
For example, beyond just the expected efficacy of CAR-Ts, the finding that CAR-Ts can be in circulation in the central nervous system provides a hope that the therapy can (a) be effective in suppressing
possible central nervous system relapses and (b) potentially be tested against primary central nervous system cancers, as well as central nervous system lymphomas. Furthermore, even though the current approved CAR-T therapies target CD19, there are data to suggest that CAR-T therapy might still be a great therapy for patients who have progressed on other CD19-targeting therapies.
Thus, the patients who have progressed on other CD19-targeting therapies still have hope. Among the main challenges associated with CAR-T therapy that still need to be addressed are the several toxicities. These toxicities have led to evaluation of the quality of life in treated patients
Source: CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas, International Journal of Molecular Science

It was a good trade, thanks everyone

If bulldog says SELL, you know what to do haha

Follow bulldog

I go make coffee first,

bulldog best trader on i3?

Thanks @bulldog I love you

Buy all shares below RM0.100

@whistlebower99 shut up

Buy

@whistlebower99 lying again

Mtronic mother share

MTRONIC mother share push

RM0.08 is so cheap to enter. Why are you guys afraid to buy>

Take big risks and buy

The Calvin Indicator is back!

Haha all retail investor scared to enter

Shut up @whistlebower99

WB keep going higher

MTRONIC-WB

Let's go

Stock buy-back

Top Glove Corporate Strategy team failed at their job

Well said by @arv18
Excellent analysis

Show us your portfolio. Go short Taiwan Semiconductor and then post a screenshot of your trade order. Then your words hold weight. Or else you are just spewing bs

You really don't know anything about geopolitics.

Keep collecting Top Glove below RM1.00
This stock literally cannot drop anymore

If I am Lim Wee Chai, I would be so angry

Top Glove has already hit the bottom. Just read the Bloomberg article, when Bloomberg or any media companies start to heavily criticise a company, you know that the bottom is in

Berjaya Food no more upside. Will trade flat and downward risk will build. Don't expect to make money from this stock, you will get played by insiders

Buy

AGESON Berhad PE 0.75
This is hilarious

Good recovery for AGES

Very good

Thank you bulldog

Warrant 300% gains

Good

Easy money indeed

Go go go

PGF

Ambank biggest benefactor
Catalyst
1. BN Wins the next General Election
2. Huge gains from selling derivatives and equity warrants
3. Interest rate rise to boost profits from consumer and SME banking
4. Corporate banking may slow
5. Transaction banking demand will remain high

Kotra Industries, Apex Healthcare.

Always buy companies with high FCF yield. Only companies with good cash flow can beat recessionary environment

Top Bursa Financials Stocks to Own in 2022

1. Ambank
2. Hong Leong Financial Group
3. Aeon Credit Berhad